House committee substitute to the 1st edition makes the following changes.

Amends the definitions that apply to Part 3, Individualized Treatments, of Article 23A of GS Chapter 90, by removing the term life-threatening or severely debilitating illness and instead separating it out into two separately defined terms and defines those terms in a way that incorporates the previous cross-reference to federal law. Defines life-threatening illness as diseases or conditions where the likelihood of death is high unless the course of the disease is interrupted and diseases or conditions where potentially fatal outcomes where the end point of clinical trial analysis is survival. Defines severely debilitating illness as diseases or conditions that cause major irreversible morbidity. 

Amends proposed new GS 90-325.24 by adding that denial of coverage by the Medicaid program is not a violation of the prohibition on a State official, employee, or agent blocking or attempting to block an eligible patient's access to an individualized investigation drug, biological product, or device.